Semax vs Mazdutide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Semax is a synthetic heptapeptide derived from ACTH developed in Russia. It is a potent nootropic that enhances memory, focus, and provides neuroprotection. Approved in Russia for cognitive disorders, stroke recovery, and traumatic brain injury.
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Half-Life
- Minutes (but effects persist for hours via BDNF induction)
- ~7 days
- Admin Route
- Intranasal, SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.25–1 mg (250–1000 mcg)
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- Frequency
- 1–2 times daily
- Once weekly
- Key Benefits
- Enhances memory and learning
- Improves focus and concentration
- Increases mental energy and motivation
- Provides neuroprotection via BDNF and NGF upregulation
- Reduces cognitive decline
- May alleviate ADHD symptoms
- Supports recovery from brain injury and stroke
- Fast-acting — effects within 30–60 minutes
- Approved in Russia for cognitive disorders and stroke recovery
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Side Effects
- Headache (rare, often from higher doses)
- Anxiety or overstimulation at high doses
- Sleep disruption if dosed too late
- Irritability (uncommon)
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Stacks With
- —
- —